GlassScriptPhysician profile
Asadullah Ahmed
NPI 1316923436
$1,681.45
in general payments reported to CMS, 2019-2025
15 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 91% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.02 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.18 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $246.72 | 2025 | Rexulti |
| Alkermes, INC. | $224.07 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $219.45 | 2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $202.87 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $138.26 | 2025 | |
| Axsome Therapeutics, INC. | $108.96 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $59.09 | 2025 | Trintellix |
| Shire North American Group INC | $57.15 | 2019 | |
| Ironshore Pharmaceuticals INC. | $45.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $36.32 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $33.70 | 2025 | Spravato, Invega Sustenna |
| Vertical Pharmaceuticals, LLC | $22.79 | 2019 | |
| Noven Therapeutics, LLC | $20.11 | 2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $15.78 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asadullah Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.